Refine by
Pulmonary Disease Articles & Analysis
103 news found
Chronic Obstructive Pulmonary Disease (COPD) is a global health burden characterized by persistent airflow limitation and progressive lung damage. ...
Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by progressive scarring of the lungs, which severely impairs lung function over time. Developing effective treatments for IPF has been a challenge for the medical community, as the mechanisms driving this disease are complex and not fully understood. To accelerate drug ...
Recent advances in the fight against severe acute inflammatory lung diseases, including COVID-19, have revealed a promising new approach to treating pulmonary hyperinflammation and long-term lung damage such as fibrosis. ...
With more than 60 years’ expertise in respiratory diagnostics, Vitalograph is the only company in the world specialized in delivering clinical trial services exclusively for pulmonary function-focused studies. Speaking about the recent additions to their portfolio of services, Richard James, Executive Vice President and Chief Operating Officer of Vitalograph Clinical Trials says: ...
The company plans to continue growing its team to power the expansion of Juvena’s drug discovery platform and advance the company’s biologics pipeline targeting chronic and age-related diseases. "We are thrilled to announce the addition of Neil, Gayathri, Mo and Eddie to the team. ...
Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today a $32M equity investment, from a large medical device innovator. ...
Chronic obstructive pulmonary disease (COPD), which includes emphysema and chronic bronchitis, makes breathing difficult for millions of Americans who have been diagnosed with the condition. The Centers for Disease Control and Prevention (CDC) reports that millions more suffer from the respiratory disease, but have not been ...
The addition of deep learning algorithms to VIDA’s LungPrint solution allows the company to improve the performance of lung imaging analysis and enable a more comprehensive assessment of disease probability and progression. This depth of insight empowers physicians to develop personalized treatment plans that can improve outcomes and quality of life. ...
Fluidda’s proprietary in silico platform FRI (Functional Respiratory Imaging) delivers quantitative predictions of regional drug deposition in disease state lungs using Computational Fluid Dynamics (CFD). The FRI platform provides critical information to help understand the availability and activity of the drug at the site of action in the lungs, when complemented by ...
ByFluidda
No identifiable prior medical treatment; Impossibility for the patient to participate in prolonged medical follow-up; Unstable psychotic disorders, severe depressive syndromes that have not been stabilized with a specific treatment, suicidal tendencies; Alcoholism or drug addiction; Severe eating disorders (such as bulimia); An insufficient mastication coefficient; Documented ...
About Tactile Medical Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. ...
The offering is orchestrated by body region and procedure, initially focusing on thoracic and neurological diseases, such as pulmonary nodule detection and triage of potential intracerebral hemorrhage (ICH) and large vessel occlusions (LVO). ICH and LVO can be associated with stroke. More disease-specific application packages will be added moving ...
ByBayer AG
(“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced the publication of an expert opinion consensus statement. ...
(“Tactile Medical”) (Nasdaq:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced that management will participate in the William Blair 42nd Annual Growth Stock Conference, which is being held at the Loews Chicago Hotel in Chicago, Il from June 6th-9th. ...
VIDA InsightsTM empowers physicians to better manage patients with or at risk of chronic obstructive pulmonary disease (COPD), interstitial lung disease, asthma, emphysema, lung cancer, and COVID-19. ...
Ventilation defect probability mapping (vDPM) is a sophisticated measure of air trapping, relevant in airway diseases such as COPD, asthma, and long COVID1. These functional measures offer valuable insights into the impact of therapy for a variety of lung conditions. ...
The difference is that the specific program of non-invasive ventilation, exercise training, and other interventions prescribed to each patient is based on his or her pulmonary disease phenotype. “Everything is tailored to the needs of the patient,” he explains. ...
ByFluidda
In early April 2022, VIDA received market authorization in Japan for its VIDA Insights software, which is a complementary data-driven solution used by lung care teams at the point of care, aiding them to detect disease early, diagnose with more confidence, make more personalized treatment decisions and use precision lung intelligence to better manage population health. ...
May 1, 2022 – Inhalation therapies, despite their prevalence in treating pulmonary diseases and respiratory-related conditions, have numerous setbacks, such as the deposition of aerosolized particles in the upper ...
About Eosinophilic Esophagitis (EoE) EoE is a chronic, progressive type 2 inflammatory disease that damages the esophagus and prevents it from working properly. ...